相关实验视频

Updated: Jan 15, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

鉴定TPRA1作为瘤病毒M1的新型受体和预测生物标志物

Linyi Hu¹, Guigen Zhang², Yuan Lin³

¹Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|October 6, 2025

概括

跨膜蛋白脂肪细胞关联1 (TPRA1) 是瘤病毒M1 (OVM) 的新型受体,增强病毒进入和癌细胞溶解. TPRA1的表达预测了OVM的敏感性,并可以指导患者选择OVM治疗.

科学领域:

瘤治疗性病毒疗法
分子病毒学分子病毒学.
癌症生物学癌症生物学

背景情况:

瘤病毒选择性地向癌细胞,病毒受体决定热带性.
识别这些受体对于优化型病毒治疗和患者选择至关重要.

研究的目的:

为了确定新型宿主细胞受体对瘤病毒M1 (OVM).
阐明已识别的受体促进病毒进入的机制.
评估已识别的受体作为OVM治疗反应的潜在生物标志物.

主要方法:

一个膜蛋白向的CRISPR-Cas9屏幕被用来识别OVM受体.
进行了涉及病毒附着,内化和结合试验的机制研究.
在细胞系,小鼠模型和来自患者的瘤样本中分析了TPRA1表达水平.

主要成果:

转膜蛋白脂肪细胞相关的1 (TPRA1) 被确定为OVM的新型受体.
TPRA1通过通过其细胞质尾巴通过糖化和内化促进病毒附着,促进OVM感染.
在各种模型中,TPRA1表达与OVM灵敏度正相关,并且在瘤中与正常组织相比上调.
TPRA1还调解了塞米利基森林病毒的进入,这表明它在阿尔法病毒感染中起着保留的作用.

结论:

TPRA1是OVM热带和病毒进入的关键决定因素.
TPRA1作为OVM治疗的潜在预测生物标志物,有助于为临床试验选择患者.
这些发现促进了对瘤病毒与宿主相互作用和治疗策略的理解.

关键词:

在TPRA1中,TPRA1是TPRA1.生物标志物生物标志物科病毒M1病毒接收器接收器接收器接收器病毒入口病毒入口.

更多相关视频

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.